Back to Search
Start Over
On the Mechanism of the Cardioprotective Action of σ1 Receptor Agonist Anxiolytic Fabomotizole Hydrochloride (Afobazole)
- Source :
- Bulletin of Experimental Biology and Medicine. 165:660-664
- Publication Year :
- 2018
- Publisher :
- Springer Science and Business Media LLC, 2018.
-
Abstract
- Original translational rat model of chronic heart failure provoked by experimental anterior transmural myocardium infarction was employed to examine the preventive action of anxiolytic Afobazole (15 mg/kg/day administered intraperitoneally during the first 15 days after coronary occlusion) on the development of the heart failure assessed in 3 months after infarction. Afobazole prevented the development of pathologic remodeling of the myocardium, maintained its inotropic function, and decreased the plasma level of brain natriuretic peptide known as a biochemical marker of chronic heart failure. In the myocardium, Afobazole down-regulated overexpression of the genes induced in chronic heart failure and assessed by corresponding RNA levels, which code angiotensin (AT1A-R), vasopressin (V1A-R), and glucocorticoid (GR) receptors as well as Epac2 protein. The revealed biochemical changes are consistent with the data on cardioprotective action of Afobazole.
- Subjects :
- 0301 basic medicine
Agonist
Inotrope
medicine.drug_class
business.industry
General Medicine
Pharmacology
Brain natriuretic peptide
medicine.disease
General Biochemistry, Genetics and Molecular Biology
03 medical and health sciences
Fabomotizole
030104 developmental biology
0302 clinical medicine
Coronary occlusion
Heart failure
Renin–angiotensin system
medicine
business
030217 neurology & neurosurgery
Glucocorticoid
medicine.drug
Subjects
Details
- ISSN :
- 15738221 and 00074888
- Volume :
- 165
- Database :
- OpenAIRE
- Journal :
- Bulletin of Experimental Biology and Medicine
- Accession number :
- edsair.doi...........1c3d5c1733e81881a4758009a2b98d4a